Clinical trial
Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
NCT00303251 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00303251 |
|---|---|
| Title | Safety of TKI258 in Advanced/Metastatic Melanoma Subjects |
| Official title | A Phase I/II Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TKI258 (CHIR-258) in Patients With Locally Advanced or Metastatic Melanoma |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | TKI258 |
| Enrollment | 47 |
| Start date | Apr 1, 2006 |
| Primary completion | Sep 1, 2009 |
| First posted | Mar 16, 2006 |
| Last update posted | Mar 11, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: